? OVERALL This is a renewal application for support of the Yale University Digestive Disease Research Core Center, a multidisciplinary Center whose research focus is Liver Structure, Function and Disease. Thirty-four independently funded investigators comprise a current digestive disease related-research base of ~$23 million, and all of these individuals actively collaborate with other Liver Center members. There are an additional 52 associate members engaged in liver-related research, 40% of whom also have independent funding. Research programs in the Center are distributed across 17 Departments of the University including Biomedical Engineering; Cell Biology; Cellular and Molecular Physiology; Comparative Medicine; Epidemiology and Public Health; Human Genetics; Immunobiology; Internal Medicine; Microbial Pathogenesis; Molecular Biophysics and Biochemistry; Obstetrics and Gynecology; Pathology; Pediatrics; Pharmacology; Radiology, Surgery, and Urology. The research base focuses on three major basic/translational themes: (1) Hepatic metabolism, (2) Immunobiology and inflammation, and (3) Epithelial biology/pathobiology. The research programs are broad and range from fundamental studies of the biology of liver and related digestive systems to translational studies of immediate clinical relevance. The major areas of liver disease examined within these translational themes include autoimmune diseases, cholestasis, fibrosis/cirrhosis, genetic diseases, infections, liver cancer, and NASH/ASH. The major goals of the Center continue to be: (1) to stimulate multidisciplinary interactions between basic and clinical faculty and departments, (2) to provide an in-depth training environment, (3) to efficiently organize time consuming, often costly techniques and procedures in Core Facilities for use by multiple investigators, (4) to stimulate basic scientists to direct their focus to areas of interest to the Center, (5) to stimulate translational research from bench to bedside, (6) to promote new research and training opportunities with a pilot feasibility program, and (7) to create an intellectual environment within the field by fostering collaborations both within and outside the institution through its enrichment program. To achieve these goals the Center is organized into four Core Facilities including: (1) Administrative Core, (2) Cellular and Molecular Physiology Core, (3) Morphology Core and (4) Clinical/Translational Core. A Pilot Feasibility Program supports one- to two-year small grants for new scientific initiatives. The Enrichment Program consists of research seminars, symposia, visiting professorships, and retreats.
? OVERALL Liver disease affects nearly one in three Americans. The Yale Liver Center's mission is to enhance knowledge of the etiology, diagnosis and treatment of liver diseases and other related disorders of the digestive system, thereby advancing the nation's public health. It does so by simulating both basic, translational and clinical research in this discipline at the University and by establishing core research facilities for use by multiple liver investigators.
|Garcia-Tsao, Guadalupe (2018) Regression of HCV cirrhosis: Time will tell. Hepatology 67:1651-1653|
|Hung, Adelina; Garcia-Tsao, Guadalupe (2018) Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int 38:1437-1441|
|Kaffe, Eleanna; Fiorotto, Romina; Pellegrino, Francesca et al. (2018) ?-Catenin and interleukin-1?-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology 67:1903-1919|
|Goldberg, David S; Levy, Cynthia; Yimam, Kidist et al. (2018) Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clin Gastroenterol Hepatol 16:591-593|
|Cadamuro, Massimiliano; Stecca, Tommaso; Brivio, Simone et al. (2018) The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1435-1443|
|Besse, Whitney; Choi, Jungmin; Ahram, Dina et al. (2018) A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat 39:378-382|
|Strazzabosco, Mario; Fiorotto, Romina; Cadamuro, Massimiliano et al. (2018) Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochim Biophys Acta Mol Basis Dis 1864:1374-1379|
|Murugesan, Vagishwari; Liu, Jun; Yang, Ruhua et al. (2018) Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells Mol Dis 68:47-53|
|Sachar, Hamita; Pichetshote, Nipaporn; Nandigam, Kavitha et al. (2018) Continued midazolam versus diphenhydramine in difficult-to-sedate patients: a randomized double-blind trial. Gastrointest Endosc 87:1297-1303|
|Bhutta, A Q; Garcia-Tsao, G; Reddy, K R et al. (2018) Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther 47:78-85|
Showing the most recent 10 out of 763 publications